<DOC>
	<DOCNO>NCT03088293</DOCNO>
	<brief_summary>This study evaluate Efficacy Safety Infliximab versus Cyclophosphamide Subjects Idiopathic Refractory Scleritis . The term scleritis describe chronic inflammation involve outermost cost skeleton eye . Scleritis classify anatomically either anterior posterior base principal location inflammation . Thirty forty percent scleritis case associate systemic autoimmune condition include rheumatoid arthritis granulomatosis polyangiitis . Infectious cause include herpes virus varicella zoster account 5 10 % patient . The remain 50 % case classify idiopathic . CIRIS , first prospective randomize , head head study , compare infliximab cyclophosphamide refractory idiopathic scleritis . There firm evidence randomize controlled trial directly address best biologic agent severe refractory idiopathic scleritis . If leave untreated insufficiently treat , scleritis progress peripheral ulcerative keratitis , uveitis glaucoma . Visual loss occur approximately 10 % patient anterior scleritis 75 % patient posterior scleritis . The incidence burden ocular inflammation ( uveitis scleritis ) dramatically reduce recent year use biologics , raise question whether compound use earlier treatment severe non infectious scleritis . Contrasting immunosuppressor , cyclophosphamide infliximab act rapidly highly effective steroid 's sparing . Despite strong rationale , compound yet approve idiopathic refractory scleritis , guarantee innovative nature study aim select drop arm evidence efficacy already exist .</brief_summary>
	<brief_title>Cyclophosphamide vs. Infliximab Refractory Idiopathic Scleritis ( CIRIS )</brief_title>
	<detailed_description />
	<mesh_term>Scleritis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>1 . Provide write , informed consent prior performance study specific procedures 2 . Male female , age ≥ 18 Screening 3 . Weight 40 120 kg ( 88.2 264 lb ) Screening 4 . Diagnosis idiopathic scleritis least one eye . Scleritis classify anatomically either anterior posterior base principal location inflammation . Clinically anterior scleritis divide diffuse , nodular necrotizing type posterior scleritis diffuse nodular type ( Watson hayreh , 1976 ) ) . 5 . Active disease : Currently uncontrolled scleritis disease . Uncontrolled scleritis disease define ( least ) 2 scleral inflammation , accord grade system define Senesclera inflammation 0 4 gradation ( Sen et al , 2011 ) : finding document drawing , photography central review . 6 . Refractory disease : At screen , subject must receive oral corticosteroid ( &gt; 10 mg/day prednisone equivalent &lt; 80mg/day ) least one immunosuppressive ( azathioprine , methotrexate , mycophenolate mofetyl , cyclosporine , leflunomide ) ; intolerant immunosuppressive therapy . 7 . Topical corticosteroid and/or NSAIDs permit provide dose regimen stable 2 week prior Screening remain stable throughout study . Topical treatment cycloplegia permit . 8 . Chest Xray result ( posteroanterior lateral ) within 12 week prior randomization visit evidence active Tuberculosis , active infection , malignancy 9 . For female subject childbearing age , negative serum pregnancy test 10 . For subject reproductive potential , willingness use contraceptive measure adequate prevent subject subject 's partner become pregnant study . Adequate contraceptive measure include hormonal method use two cycle prior Screening ( e.g. , oral contraceptive pill , contraceptive patch , contraceptive vaginal ring ) , barrier method ( e.g. , contraceptive sponge , diaphragm use conjunction contraceptive foam jelly , condom use conjunction contraceptive foam jelly ) , intrauterine method ( IUD ) , sterilization ( e.g. , tubal ligation monogamous relationship vasectomize partner ) , abstinence . 11 . A negative QuantiFERON®Tuberculosis ( TB ) test result event QuantiFERON®TB test result screen positive subject must agree complete INH treatment course least 6 month 12 . Affiliated National French social security system 1 . Infectious scleritis , scleritis related systemic disease ( i.e granulomatosis polyangiitis , rheumatoid arthritis , lupus , relapse chondritis… . ) 2 . Monocular patient 3 . Active tuberculosis history untreated tuberculosis 4 . Known positive syphilis serology , HIV antibody , hepatitis B surface antigen antinucleocapsid antibody hepatitis B virus , and/or hepatitis C antibody . 5 . History malignancy within 5 year prior Screening carcinoma situ cervix adequately treat , nonmetastatic squamous basal cell carcinoma skin . 6 . History severe allergic anaphylactic reaction monoclonal antibody 7 . Infectious disease : 1 . Fever infection require treatment antibiotic within 3 week prior Screening Screening Day 0 2 . History recurrent infection predisposition infection 8 . Known immunodeficiency 9 . History multiple sclerosis and/or demyelinate disorder 10 . Laboratory value assess Screening : 1 . Hemoglobin &lt; 8.5 g/dL 2 . WBC &lt; 3.0 x 103/mm3 3 . Platelet count &lt; 100 x 103/mm3 4 . Glomerular filtration rate ( GFR ) &lt; 30ml/min . 5 . AST/ALT &gt; 1.5 x upper limit normal ( ULN ) 6 . Absolute Neutrophil Count &lt; 2.0 x 103/mm3 7 . Absolute Lymphocyte Count &lt; 0.5 x 103/mm3 11 . Use follow systemic treatment specify period : 1 . Any previous systemic biologic therapy , include antiTNF 2 . Treatment systemic alkylating agent within 12 month prior Screening Screening Day 0 ( e.g. , cyclophosphamide , chlorambucil ) 3 . Any live ( attenuate ) vaccine within 3 month prior Screening Screening Day 0 ; recombinant kill virus vaccine permit . Live seasonal flu H1N1 vaccine permit ≥ 2 week prior Screening . 12 . Inability understand information protocol 13. pregnant lactate woman 14. patient guardianship</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>idiopathic refractory scleritis</keyword>
	<keyword>infliximab</keyword>
	<keyword>cyclophosphamide</keyword>
</DOC>